Curis Names Ali Fattaey, Ph.D. as President and COO

Curis CRIS, an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced the appointment of Ali Fattaey, Ph.D., as President and Chief Operating Officer. Dr. Fattaey will join Curis' senior management team, where he will help guide and further advance Curis' overall corporate strategic goals and will also be responsible for the oversight and implementation of the Company's research and development operations. Dan Passeri will continue to serve as Chief Executive Officer and Michael Gray will continue to serve as Chief Financial Officer. Dr. Fattaey has held leadership positions at several cancer-focused organizations and brings significant research and development experience to Curis, including eight years at Onyx Pharmaceuticals, Inc., where he was responsible for multiple programs in partnership with Pfizer, Inc. (then Parke-Davis/Warner-Lambert) and Bayer HealthCare, which led to the discovery and development of Nexavar® (sorafenib), now approved by the FDA for the treatment of advanced renal cell carcinoma and unresectable hepatocellular cancer. In addition, Dr. Fattaey led the discovery of palbociclib, a small molecule See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!